A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

NCT04898634 · clinicaltrials.gov ↗
PHASE1
Phase
ACTIVE_NOT_RECRUITING
Status
216
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Janssen Research & Development, LLC